View clinical trials related to Prostate Cancer.
Filter by:The purpose of this study is to see how safe Androderm® (the study drug) is at three different doses in subjects with early hormone refractory prostate cancer. In addition, information about hormonal levels and the effects of testosterone on quality of life including sexual functioning and muscle strength will be collected.
RATIONALE: Gathering information about patients with prostate cancer may help doctors learn more about how patients choose treatment options. PURPOSE: This study is looking at treatment choice in patients with localized prostate cancer.
Nowadays, prostate cancer screening is largely widespread although it is not recommended yet. This screening includes primarily digital rectal examination and PSA. Recently, a new specific genetic marker of prostate cancer has been discovered. It is PCA-3 gene. The main objective is to evaluate prospectively this new marker in patients treated for prostatic pathology (benign or malign) in the department.
Social comparisons may function as a coping strategy, but their role in coping and quality of life has not been well characterized. The purpose of the current study is to investigate the relationships between cognitive appraisals; coping strategies; social comparisons; and quality of life among men with prostate cancer. The conceptual framework for this study is drawn from Festinger s Social Comparison Theory, Lazarus and Folkman s Transactional Model of Stress and Coping, and Mishel s Uncertainty in Illness Theory. A cancer diagnosis is accompanied by uncertainty about how cancer will affect one s life. Theory and empirical data suggest that in conditions of uncertainty, coping affects adjustment to a condition. Social comparisons have been postulated to be more prevalent in uncertain situations. Because little is known about how social comparisons operate, participants in this study will be recruited exclusively from prostate cancer support groups. Support groups provide a context in which individuals are likely to make social comparisons and to be cognizant of these comparisons. Prostate cancer provides a model of a common, chronic condition with complex etiology. Prostate cancer treatment may cause sexual, urinary, and bowel side effects, which may affect patients quality of life and elicit attempts to cope. One way of managing the prostate cancer experience may be to compare oneself to others who are doing better or worse than oneself on relevant dimensions. The interpretation of social comparisons may positively or negatively affect one s perceived quality of life. There have been no studies among prostate cancer patients that have quantitatively measured the use of social comparisons. There is also a paucity of research in this population regarding the predictors of coping strategies and the predictors of quality of life across multiple domains. This study will use a cross-sectional, mixed methods survey to investigate relationships between cognitive appraisals, coping, and quality of life and to qualitatively explore social comparisons among men with prostate cancer. Participants may complete the survey on paper or online. The primary outcomes are the use of coping strategies, including social comparisons, and quality of life. Individuals with a personal or family history of prostate cancer are currently seen by genetic counselors as part of research studies investigating the genetic basis of prostate cancer. If relationships are demonstrated between the social comparisons and quality of life, genetic counselors may want to assess patients social comparisons to evaluate how patients are coping with their condition.
Background: - GE-148 (18F) is a new drug that is designed to attach to prostate cancer cells. Researchers are interested in combining the drug with a small amount of radioactive material to allow prostate cancer lesions to appear more clearly on imaging scans. Researchers are also interested in determining whether the combination can help make cancer cells in pelvic lymph nodes easier to detect through imaging studies. GE-148 (18F) will be used to examine individuals who are scheduled to have surgery on their prostate cancer. Objectives: - To evaluate the effectiveness of GE-148 (18F) in detecting prostate cancer and cancer cells in pelvic lymph nodes using positron emission tomography and magnetic resonance imaging scanning. Eligibility: - Men at least 18 years of age who have been diagnosed with prostate cancer and are scheduled to have prostate removal surgery. Design: - Participants will be screened with a physical examination, medical history, blood tests, and imaging studies. - Participants will have magnetic resonance imaging (MRI) and positron emission tomography (PET) scans with GE-148 (18F) prior to their scheduled surgery. The MRI and PET scans may be performed on the same day or on different days, depending on the schedule set by the study researchers. - Tissue samples taken during prostate removal surgery, including prostate tissue and pelvic lymph nodes, will be collected for further study of the effectiveness of GE-148 (18F).
The purpose of this study is to study the molecular effects of the chemopreventative agent, finasteride, in combination with dietary soy supplementation in patients at high risk for the development of prostate cancer. Also, the investigators intend to create a large database with health information from men who are at high risk of developing prostate cancer, along with serum and tissue samples from those patients who are willing to provide tissue and serum samples.
This is a clinical research study of an investigational (FDA IND-BB 10091) treatment of subjects with castration-resistant prostate cancer resistant to Taxanes (docetaxel, cabazitaxel) and evidence of disease progression on androgen-axis inhibition and/or immunotherapy in the form of sipuleucel-T. The treatment is being evaluated for its effect on tumor growth. It consists of the placement (implantation) of small beads that contain mouse renal adenocarcinoma cells (RENCA macrobeads). The cells in the macrobeads produce substances that have been shown to slow or stop the growth of tumors in experimental animals and veterinary patients. It has been tested in 31 human subjects with different types of cancers in a Phase I safety trial. Phase II studies in patients with colorectal, pancreatic or prostate cancers are in progress.
RATIONALE: Temsirolimus and vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving temsirolimus together with vorinostat may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of temsirolimus and vorinostat in treating patients with metastatic prostate cancer.
This study compares the ability of a new design of brachytherapy seed for prostate seed implants for treatment of prostate cancer to maintain their intended position in the prostate after being deposited. Standard seeds, especially in apical locations, have a tendency to migrate distally in response to muscular forces. AnchorSeeds have a textured coating which is designed to prevent migration. 40 patients who are eligible and suitable for prostate brachytherapy will be randomly assigned to receive either standard seeds or AnchorSeeds.
Prostate Cancer is the most common cancer in men, affecting about as many men as women diagnosed with breast cancer, and killing about as many men per year as breast cancer kills women. The most common surgical treatment is prostatectomy, the removal of the prostate. During prostate surgery, tumor remains at the edge of the surgery, called residual tumor, in 30% of all prostatectomies. Such patients have a significantly higher risk of local recurrence of the cancer, and higher rates of death. In contrast, even patients with cancer outside of the prostate, but still nearby the prostate, do better when the margins are made clean of tumor during surgery. The investigators propose to reduce the number of patients with residual tumor after surgery. The investigators will test in patients a fluorescent molecule that allows cancer to be detected during surgery. If this trial works as designed, the investigators will reduce the number of patients who have to receive additional treatment, such as high doses of radiation to the lower abdomen, because the amount of residual tumor left behind has been minimized. This may also lead to higher rates of survival. This type of detection of cancer the investigators employ is called Molecular imaging. The investigators believe that molecular imaging will be the key to improved diagnosis, individualized treatment selection, and treatment monitoring. If successful, a large human trial will be conducted after this study with a corporate imaging partner.